Cover Image
市場調查報告書

腫瘤/癌症治療藥的全球市場 - 規模,佔有率,趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔及預測 (2013∼2020年)

Global Oncology/Cancer Drugs Market (Therapeutic Modalities, Cancer Types and Geography) - Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

出版商 Allied Market Research 商品編碼 329491
出版日期 內容資訊 英文 159 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腫瘤/癌症治療藥的全球市場 - 規模,佔有率,趨勢,企業簡介,需求,考察,分析,調查,報告,機會,市場區隔及預測 (2013∼2020年) Global Oncology/Cancer Drugs Market (Therapeutic Modalities, Cancer Types and Geography) - Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
出版日期: 2015年02月15日 內容資訊: 英文 159 Pages
簡介

全球腫瘤/癌症治療藥市場預測將在2020年前達到1,119億美元的規模。由於Herceptin,Ervitux,Rituxan,Avastin等主要藥物的專利失效,2020年前生技仿製藥市場可望成長。同時因為其高效能及對標的的作用、及低毒性,一般認為生物學療法將獨佔市場。

本報告提供全球腫瘤/癌症治療藥市場相關調查,提供您市場現狀與2020年前的發展預測,彙整競爭趨勢,及簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 新的免疫腫瘤藥物產品的開發
  • 主要調查結果
  • 波特五力分析
  • 價值鏈分析
  • 政府的法規與給付
  • 專利分析
  • 市場佔有率分析 (2013年)
  • 癌症治療藥臨床實驗
  • 市場趨勢
    • 促進成長要素
    • 阻礙要素
    • 機會

第4章 各種治療模式全球腫瘤/癌症治療藥市場

  • 化療
  • 標靶治療
  • 免疫療法 (生物學的療法)
  • 荷爾蒙療法
  • 其他

第5章 癌症類別全球腫瘤/癌症治療藥市場

  • 血液癌症
  • 乳癌
  • 腸胃系統的癌症
  • 前列腺癌
  • 呼吸系統/肺癌
  • 皮膚癌
  • 其他

第6章 各地區全球腫瘤/癌症治療藥市場

  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲

第7章 企業簡介

  • Amgen Inc
  • Johnson and Johnson
  • Roche Diagnostics
  • GlaxoSmithKline PLC
  • Merck & Company
  • Novartis AG
  • Pfizer
  • Sanofi
  • Eli Lilly and Company
  • Celgene Corporation

圖表

目錄
Product Code: PH 15121

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies would restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the market growth.

The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.

Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.

Key companies profiled in the report are Roche diagnostics, Novartis AG, Celgene Corporation, AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co. and GlaxoSmithKline. Companies operating in the cancer drugs market focus on several strategies such as collaboration, approval and acquisition.KEY BENEFITS

The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on

The report helps in understanding the strategies adopted by various companies for gaining market share in the cancer drugs market

The report provides comprehensive analysis of factors that drive and restrict the growth of the cancer drugs market

Market conditions of cancer drugs market across all geographic regions are comprehensively analyzed

Competitive intelligence (of leading manufacturers) helps in understanding the competitive scenario across the geographies

SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies

MARKET SEGMENTATION

  • The cancer drugs market is segmented by the therapeutic modalities, cancer types and geography.

MARKET BY THERAPEUTIC MODALITIES

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others

MARKET BY CANCER TYPES

  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Respiratory/Lung Cancer
  • Skin Cancer
  • Other Cancers

MARKET BY GEOGRAPHY

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Others
  • Asia-Pacific
  • India
  • China
  • Japan
  • Australia
  • Others
  • LAMEA
  • GCC (Gulf Corporation Council)
  • Others

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segment
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

  • 2.1. Market beyond what to expect by 2025
    • 2.1.1. Moderate growth scenario
    • 2.1.2. Rapid growth scenario
    • 2.1.3. Diminishing growth scenario

CHAPTER 3 - MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Development of novel immuno-oncology drug products
  • 3.3. Key findings
    • 3.3.1. Top Factors impacting oncology drugs market
    • 3.3.2. Top investment pockets of oncology drugs market
    • 3.3.3. Top winning strategies of oncology drugs market
  • 3.4. Porter's five forces analysis
    • 3.4.1. Bargaining power of buyers (low)
    • 3.4.2. Bargaining power of suppliers (moderate)
    • 3.4.3. Threat of new entrants (Low)
    • 3.4.4. Threat of substitutes (moderate)
    • 3.4.5. Intense competitive rivalry
  • 3.5. Value chain analysis
    • 3.5.1. Primary activities
    • 3.5.2. Support activities
  • 3.6. Government regulations and reimbursement
    • 3.6.1. Regulations in United States
    • 3.6.2. Regulations in Europe
    • 3.6.3. Regulations in Asia-Pacific
    • 3.6.4. Reimbursement scenario
  • 3.7. Patent analysis
    • 3.7.1. Patent Analysis by type of patents
    • 3.7.2. Patent analysis by geography
  • 3.8. Market share analysis, 2013
  • 3.9. Clinical trials for oncology drugs
  • 3.10. Market dynamics
    • 3.10.1. Drivers
      • 3.10.1.1. Rising incidence and prevalence of various cancer types
      • 3.10.1.2. Growing importance of biological and targeted drug therapies
      • 3.10.1.3. Expiration of key patents and biosimilars impact
      • 3.10.1.4. Acquisitions and collaborations - bolt-on strategies driving the market growth
    • 3.10.2. Restraints
      • 3.10.2.1. High cost of drug development and threat of failure
      • 3.10.2.2. Adverse effects of anti-cancer drug therapy
    • 3.10.3. Opportunities
      • 3.10.3.1. Advancement of anti-cancer drugs research
      • 3.10.3.2. Personalized medicine approach

CHAPTER 4 - GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES

  • 4.1. Chemotherapy
    • 4.1.1. Key market trends
    • 4.1.2. Key growth factors and opportunities
    • 4.1.3. Market size and forecast
  • 4.2. Targeted therapy
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. Immunotherapy (biologics therapy)
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. Hormonal therapy
    • 4.4.1. Key market trends
    • 4.4.2. Key growth factors and opportunities
    • 4.4.3. Market size and forecast
  • 4.5. Others
    • 4.5.1. Market size and forecast

CHAPTER 5 - GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES

  • 5.1. Blood cancer
    • 5.1.1. Epidemiology - prevalence and incidence
    • 5.1.2. Trends in blood cancer treatment
    • 5.1.3. Market size and forecast
  • 5.2. Breast cancer
    • 5.2.1. Epidemiology - prevalence and incidence
    • 5.2.2. Trends in breast cancer treatment
    • 5.2.3. Market size and forecast
  • 5.3. Gastrointestinal cancer
    • 5.3.1. Epidemiology - prevalence and incidence
    • 5.3.2. Trends in treatment of gastrointestinal cancer
    • 5.3.3. Market size and forecast
  • 5.4. Prostate cancer
    • 5.4.1. Epidemiology - prevalence and incidence
    • 5.4.2. Trends in treatment of prostate cancer
    • 5.4.3. Market size and forecast
  • 5.5. Respiratory/lung cancer
    • 5.5.1. Epidemiology - prevalence and incidence
    • 5.5.2. Trends in treatment of lung Cancer
    • 5.5.3. Market size and forecast
  • 5.6. Skin cancer
    • 5.6.1. Epidemiology - prevalence and incidence
    • 5.6.2. Trends in treatment of skin cancer
    • 5.6.3. Market size and forecast
  • 5.7. Other cancers
    • 5.7.1. Trends in treatment of other cancer types

CHAPTER 6 - GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY

  • 6.1. North America
    • 6.1.1. Market size and forecast
    • 6.1.2. United States
      • 6.1.2.1. Key market trends
      • 6.1.2.2. Market size and forecast
    • 6.1.3. Canada
      • 6.1.3.1. Key market trends
      • 6.1.3.2. Market size and forecast
    • 6.1.4. Mexico
      • 6.1.4.1. Market size and forecast
  • 6.2. Europe
    • 6.2.1. Key market trends
    • 6.2.2. Market size and forecast
    • 6.2.3. Germany
      • 6.2.3.1. Key market trends
      • 6.2.3.2. Market size and forecast
    • 6.2.4. France
      • 6.2.4.1. Key market trends
      • 6.2.4.2. Market size and forecast
    • 6.2.5. United Kingdom
      • 6.2.5.1. Key market trends
      • 6.2.5.2. Market size and forecast
    • 6.2.6. Others
      • 6.2.6.1. Key market trends
      • 6.2.6.2. Market size and forecast
  • 6.3. Asia Pacific
    • 6.3.1. Key market trends
      • 6.3.1.1. Market size and forecast
    • 6.3.2. India
      • 6.3.2.1. Key market trends
      • 6.3.2.2. Market size and forecast
    • 6.3.3. China
      • 6.3.3.1. Key market trends
      • 6.3.3.2. Market size and forecast
    • 6.3.4. Japan
      • 6.3.4.1. Key market trends
      • 6.3.4.2. Market size and forecast
    • 6.3.5. Australia
      • 6.3.5.1. Key market trends
      • 6.3.5.2. Market size and forecast
    • 6.3.6. Others
  • 6.4. LAMEA
    • 6.4.1. GCC (gulf corporation council)
      • 6.4.1.1. Key Market Trends
      • 6.4.1.2. Market size and forecast
    • 6.4.2. Others
      • 6.4.2.1. Market size and forecast

CHAPTER 7 - COMPANY PROFILES

  • 7.1. Amgen Inc.
    • 7.1.1. Company overview
    • 7.1.2. Amgen Inc. snapshot
    • 7.1.3. Financial performance
    • 7.1.4. Operating business segment overview
    • 7.1.5. Key strategies and development
    • 7.1.6. SWOT analysis
  • 7.2. Johnson and Johnson
    • 7.2.1. Company overview
    • 7.2.2. Johnson & Johnson snapshot
    • 7.2.3. Operating business segment overview
    • 7.2.4. Financial performance
    • 7.2.5. Key strategies moves and development
    • 7.2.6. SWOT Analysis
  • 7.3. Roche Diagnostics
    • 7.3.1. Company overview
    • 7.3.2. Roche Diagnostics snapshot
    • 7.3.3. Operating business segment overview
    • 7.3.4. Financial performance
    • 7.3.5. Key strategies moves and development
    • 7.3.6. SWOT analysis
  • 7.4. GlaxoSmithKline PLC
    • 7.4.1. Company overview
    • 7.4.2. GlaxoSmithKline PLC Snapshot
    • 7.4.3. Operating business segment overview
    • 7.4.4. Financial performance
    • 7.4.5. Key strategies move and development
    • 7.4.6. SWOT Analysis of GlaxoSmithKline PLC
  • 7.5. Merck & Company
    • 7.5.1. Company overview
    • 7.5.2. Merck & Company snapshot
    • 7.5.3. Operating business segment overview
    • 7.5.4. Financial performance
    • 7.5.5. Key strategies move and development
    • 7.5.6. SWOT analysis
  • 7.6. Novartis AG
    • 7.6.1. Company overview
    • 7.6.2. Novartis AG snapshot
    • 7.6.3. Operating business segment overview
    • 7.6.4. Financial performance
    • 7.6.5. Key strategies move and development
    • 7.6.6. SWOT analysis
  • 7.7. Pfizer
    • 7.7.1. Company overview
    • 7.7.2. Pfizer snapshot
    • 7.7.3. Operating business segment overview
    • 7.7.4. Financial performance
    • 7.7.5. Key strategies move and development
    • 7.7.6. SWOT analysis
  • 7.8. Sanofi
    • 7.8.1. Company overview
    • 7.8.2. Sanofi snapshots
    • 7.8.3. Operating business segment overview
    • 7.8.4. Financial performance
    • 7.8.5. Key strategies move and development
    • 7.8.6. SWOT analysis
  • 7.9. Eli Lilly and Company
    • 7.9.1. Company overview
    • 7.9.2. Eli Lilly and company snapshots
    • 7.9.3. Operating business segment overview
    • 7.9.4. Financial performance
    • 7.9.5. Key strategies move and development
    • 7.9.6. SWOT analysis
  • 7.10. Celgene Corporation
    • 7.10.1. Company overview
    • 7.10.2. Celgene corporation snapshots
    • 7.10.3. Operating business segment overview
    • 7.10.4. Financial performance
    • 7.10.5. Key strategies move and development
    • 7.10.6. SWOT analysis

List of Tables

  • TABLE 1: MODERATE GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 - 2025, ($MILLION)
  • TABLE 2: RAPID GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 - 2025, ($MILLION)
  • TABLE 3: DIMINISHING GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 - 2025, ($MILLION)
  • TABLE 4: APPLICABLE STANDARDS FOR THE UNITED STATES ANTICANCER DRUG DEVELOPMENT PROCESS
  • TABLE 5: INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
  • TABLE 6: CLINICAL LABORATORY FEE SCHEDULE (CLFS) REIMBURSEMENT CODES
  • TABLE 7: CLINICAL TRIALS FOR ONCOLOGY DRUGS
  • TABLE 8: WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (EXCLUDING NON-MELANOMA SKIN CANCER) (2012)
  • TABLE 9: LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
  • TABLE 10: LIST OF KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
  • TABLE 11: LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF ANTI-CANCER DRUGS
  • TABLE 12: GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 13: GLOBAL CHEMOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 14: GLOBAL TARGETED THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 15: CANCER IMMUNOTHERAPEUTICS AND THEIR CUMULATIVE PRICES
  • TABLE 16: GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 17: GLOBAL HORMONAL THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 18: GLOBAL OTHER THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 19: GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES, 2013 - 2020 ($MILLION)
  • TABLE 20: INCIDENCE AND PREVALENCE OF BLOOD CANCER TYPES IN UNITED STATES
  • TABLE 21: USFDA APPROVED DRUGS FOR THE TREATMENT OF BLOOD CANCERS
  • TABLE 22: GLOBAL BLOOD CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 23: WORLDWIDE INCIDENCE AND PREVALENCE OF BREAST CANCER (2012)
  • TABLE 24: GLOBAL BREAST CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 25: WORLDWIDE INCIDENCE AND PREVALENCE OF GASTROINTESTINAL CANCER (2012)
  • TABLE 26: GLOBAL GASTROINTESTINAL CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 27: WORLDWIDE INCIDENCE AND PREVALENCE OF PROSTATE CANCER (2012)
  • TABLE 28: DRUGS USED IN PROSTATE CANCER AND THEIR REVENUE (2013)
  • TABLE 29: GLOBAL PROSTATE CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 30: WORLDWIDE INCIDENCE AND PREVALENCE OF LUNG CANCER (2012)
  • TABLE 31: LIST OF NEW THERAPEUTIC AGENTS FOR LUNG CANCER TREATMENT
  • TABLE 32: GLOBAL RESPIRATORY/LUNG CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 33: GLOBAL SKIN CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 34: WORLDWIDE INCIDENCE AND PREVALENCE OF CERVICAL CANCER (2012)
  • TABLE 35: GLOBAL OTHER CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 36: GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 37: NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 38: COSTS PER THERAPY OF THE COMMON CANCER DRUGS IN THE UNITED STATES:
  • TABLE 39: UNITED STATES ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 40: CANADA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 41: MEXICO ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 42: NEW ANTICANCER DRUGS APPROVED BY E MA 2013
  • TABLE 43: EUROPE ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 - 2020 ($MILLION)
  • TABLE 44: GERMANY ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 45: FRANCE ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 46: UNITED KINGDOM ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 47: OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 48: ASIA PACIFIC ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 - 2020 ($MILLION)
  • TABLE 49: INDIA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 50: CHINA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 51: JAPAN ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 52: AUSTRALIA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 53: OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 54: LAMEA ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 - 2020 ($MILLION)
  • TABLE 55: GCC ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 - 2020 ($MILLION)
  • TABLE 56: LATIN AMERICAN/ AFRICAN COUNTRIES AND THEIR PRICING POLICIES FOR CANCER THERAPIES
  • TABLE 57: OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 - 2020 ($MILLION)
  • TABLE 58: AMGEN INC. SNAPSHOT
  • TABLE 59: JOHNSON & JOHNSON SNAPSHOT
  • TABLE 60: JOHNSON AND JOHNSON OPERATING SEGEMENTS
  • TABLE 61: ROCHE DIAGNOSTICS SNAPSHOT
  • TABLE 62: ROCHE DIAGNOSTICS OPERATING SEGEMENTS
  • TABLE 63: GLAXOSMITHKLINE PLC SNAPSHOT
  • TABLE 64: GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
  • TABLE 65: MERCK & COMPANY SNAPSHOT
  • TABLE 66: MERCK & CO. OPERATING SEGEMENTS
  • TABLE 67: NOVARTIS AG SNAPSHOT
  • TABLE 68: NOVARTIS AG OPERATING SEGEMENTS
  • TABLE 69: PFIZER SNAPSHOT
  • TABLE 70: PFIZER OPERATING SEGEMENTS
  • TABLE 71: SANOFI SNAPSHOTS
  • TABLE 72: SANOFI OPERATING SEGEMENTS
  • TABLE 73: ELI LILLY AND COMPANY SNAPSHOTS
  • TABLE 74: ELI LILLY AND COMPANY OPERATING SEGEMENTS
  • TABLE 75: CELGENE CORPORATION SNAPSHOTS

List of Figures

  • FIG. 1: IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN MODERATE GROWTH SCENARIO
  • FIG. 2: IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN RAPID GROWTH SCENARIO
  • FIG. 3: IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN DIMINISHING GROWTH SCENARIO
  • FIG. 4: TOP FACTORS IMPACTING ONCOLOGY DRUGS MARKET (2014-2020)
  • FIG. 5: TOP INVESTMENT POCKETS OF ONCOLOGY/CANCER DRUGS MARKET (2013)
  • FIG. 6: TOP WINNING STRATEGIES FOR GLOBAL ONCOLOGY DRUG MARKET (2011-2013)
  • FIG. 7: TOP WINNING STRATEGIRS BY SUBTYPE
  • FIG. 8: PORTERS FIVE FORCES ANALYSIS OF ONCOLOGY DRUGS MARKET
  • FIG. 9: VALUE CHAIN ANALYSIS OF GLOBAL CANCER DRUGS MARKET
  • FIG. 10: PATENT ANALYSIS BY TYPE OF PATENTS (2011-2015)
  • FIG. 11: PATENT ANALYSIS BY GEOGRAPHY (2011-2015)
  • FIG. 12: MARKET SHARE ANALYSIS OF GLOBAL ONCOLOGY DRUG MARKET (2013)
  • FIG. 13: PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
  • FIG. 14: AMGEN INC. REVENUE BY GEOGRAPHY (2013)
  • FIG. 15: AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2013)
  • FIG. 16: SWOT ANALYSIS OF AMGEN INC.
  • FIG. 17: FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
  • FIG. 18: FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
  • FIG. 19: SWOT ANALYSIS OF JOHNSON & JOHNSON
  • FIG. 20: FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
  • FIG. 21: ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
  • FIG. 22: SWOT ANALYSIS OF ROCHE DIAGNOSTICS
  • FIG. 23: GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2013)
  • FIG. 24: GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2013)
  • FIG. 25: SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
  • FIG. 26: MERCK & CO. REVENUE BY GEOGRAPHY (2013)
  • FIG. 27: MERCK & CO. REVENUE BY BUSINESS UNITS (2013)
  • FIG. 28: SWOT ANALYSIS OF MERCK & COMPANY
  • FIG. 29: NOVARTIS AG REVENUE BY GEOGRAPHY (2013)
  • FIG. 30: NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2013)
  • FIG. 31: SWOT ANALYSIS OF NOVARTIS AG
  • FIG. 32: PFIZER REVENUE BY GEOGRAPHY (2013)
  • FIG. 33: PFIZER REVENUE BY BUSINESS SEGMENTS (2013)
  • FIG. 34: SWOT ANALYSIS OF PFIZER
  • FIG. 35: SANOFI REVENUE BY GEOGRAPHIES (2013)
  • FIG. 36: SANOFI REVENUE BY BUSINESS SEGMENTS (2013)
  • FIG. 37: SWOT ANALYSIS OF SANOFI
  • FIG. 38: ELI LILLY AND COMPANY REVENUE BY GEOGRAPHIES (2013)
  • FIG. 39: ELI LILLY AND COMPANY REVENUE BY BUSINESS SEGMENTS (2013)
  • FIG. 40: SWOT ANALYSIS OF ELI LILLY AND COMAPANY
  • FIG. 41: CELGENE CORPORATION REVENUE BY GEOGRAPHIES (2013)
  • FIG. 42: CELEGENE CORPORATION REVENUE BY PRODUCT SALES (2013)
  • FIG. 43: SWOT ANALYSIS OF CELGENE CORPORATION
Back to Top